Equities research analysts expect Athenex Inc (NASDAQ:ATNX) to announce earnings of ($0.52) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Athenex’s earnings. Athenex posted earnings per share of ($0.45) in the same quarter last year, which suggests a negative year over year growth rate of 15.6%. The company is scheduled to announce its next quarterly earnings report on Thursday, November 5th.
On average, analysts expect that Athenex will report full year earnings of ($1.77) per share for the current year. For the next year, analysts anticipate that the company will post earnings of ($1.56) per share, with EPS estimates ranging from ($2.47) to ($1.13). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Athenex.
Athenex (NASDAQ:ATNX) last released its earnings results on Thursday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.19). Athenex had a negative return on equity of 73.35% and a negative net margin of 82.63%. The business had revenue of $40.17 million for the quarter, compared to analyst estimates of $21.20 million.
In related news, major shareholder Perceptive Advisors Llc bought 200,000 shares of the stock in a transaction on Thursday, September 10th. The shares were purchased at an average price of $11.24 per share, for a total transaction of $2,248,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Manson Fok bought 16,491 shares of the stock in a transaction on Saturday, September 12th. The shares were bought at an average price of $11.03 per share, for a total transaction of $181,895.73. Following the acquisition, the director now owns 1,999,609 shares in the company, valued at approximately $22,055,687.27. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 2,030,941 shares of company stock worth $22,394,986. Insiders own 16.30% of the company’s stock.
A number of large investors have recently made changes to their positions in ATNX. Orbimed Advisors LLC grew its holdings in Athenex by 44.6% during the 1st quarter. Orbimed Advisors LLC now owns 4,009,346 shares of the company’s stock valued at $31,032,000 after buying an additional 1,237,125 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Athenex during the 3rd quarter valued at $7,382,000. Two Sigma Investments LP lifted its stake in shares of Athenex by 786.3% during the 1st quarter. Two Sigma Investments LP now owns 306,075 shares of the company’s stock worth $2,369,000 after purchasing an additional 271,542 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Athenex by 23.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 671,089 shares of the company’s stock worth $9,234,000 after purchasing an additional 125,934 shares during the period. Finally, Two Sigma Advisers LP lifted its stake in shares of Athenex by 106.4% during the 1st quarter. Two Sigma Advisers LP now owns 232,237 shares of the company’s stock worth $1,798,000 after purchasing an additional 119,700 shares during the period. Hedge funds and other institutional investors own 55.75% of the company’s stock.
NASDAQ ATNX traded up $0.08 on Friday, hitting $12.51. 368,104 shares of the company’s stock were exchanged, compared to its average volume of 689,382. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.24 and a quick ratio of 2.77. The firm’s 50-day moving average price is $12.49 and its two-hundred day moving average price is $11.32. Athenex has a fifty-two week low of $5.63 and a fifty-two week high of $18.35. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -8.51 and a beta of 0.87.
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
Featured Story: How is net asset value different from market price?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.